7421-40-1
基本信息
18β-甘草次酸半琥珀酸酯二钠
卡柏若克索龙
甘珀酸钠
CARBENOXOLONE DISODIUM SALT
CARBENOXOLONE SODIUM
18-beta-glycyrrhetinicacidhydrogensuccinate,disodiumsalt
20-beta)-3-bet
3-beta-hydroxy-11-oxoolean-12-en-30-oicacidhydrogensuccinate,disodiumsal
3-o-(beta-carboxypropionyl)-11-oxo-18-beta-olean-12-en-30-oicacid,disodium
disodiumglycyrrhetinylsuccina
duogastrone
glycyrrhetinicacidhydrogensuccinate,disodiumsalt
neogel
olean-12-en-29-oicacid,3-(3-carboxy-1-oxopropoxy)-11-oxo-,disodiumsalt,(
olean-12-en-30-oicacid,3-beta-hydroxy-11-oxo-,hydrogensuccinate,disodiums
pyrogastrone
sanodin
sodium3-beta-hydroxy-11-oxo-12-oleanen-30-oatesodiumsuccinate
sodiumcarbenoxolone
ulcus-tablinen
carbenoxolone disodium
disodium 4-(20-carboxylato-11-oxo-30-beta-norolean-12-en-3-yloxy)-4-oxobutyrate
物理化学性质
| 熔点 | >275°C (dec.) |
| 储存条件 | 2-8°C |
| 储存条件 | 2-8°C |
| 溶解度 | 少许溶于甲醇和水 |
| 酸度系数(pKa) | pKa1 4.18; pKa2 5.52(at 25℃) |
| 形态 | 固体 |
| 颜色 | 白色至灰白色 |
| 水溶解性 | Soluble in water to 100 mM. |
| 稳定性 | 吸湿性 |
| 化妆品成分功效 | SURFACTANT - CLEANSING SKIN CONDITIONING SURFACTANT - FOAM BOOSTING |
| InChIKey | BQENDLAVTKRQMS-FDPMUVMVSA-L |
| SMILES | [Na].[H][C@@]12C[C@](C)(CC[C@]1(C)CC[C@]3(C)C2=CC(=O)[C@]4([H])[C@@]5(C)CC[C@H](OC(=O)CCC(O)=O)C(C)(C)[C@]5([H])CC[C@@]34C)C(O)=O |
| LogP | 7.083 (est) |
| CAS 数据库 | 7421-40-1(CAS DataBase Reference) |
安全数据
| 危险性符号(GHS) | ![]() GHS07 |
| 警示词 | 警告 |
| 危险性描述 | H319 |
| 防范说明 | P305+P351+P338 |
| 危险品标志 | Xn,Xi |
| 危险品标志 | Xn |
| 危险类别码 | 22-36 |
| 危险类别码 | R22-R36 |
| 安全说明 | 26-36 |
| 安全说明 | S26-S36 |
| WGK Germany | 3 |
| WGK Germany | 3 |
| RTECS号 | RK0250000 |
| 存储类别 | 11 - Combustible Solids |
| 危险性类别 | Eye Irrit. 2 |
| 毒性 | LD50 in male mice (mg/kg): 198 i.v.; 120 i.p.; in male rats (mg/kg): 3200 orally (Robson, Sullivan) |
7421-40-1(安全特性,毒性,储运)
知名试剂公司产品信息
甘珀酸钠价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2026/09/15 | HY-B1367 | 甘珀酸钠 Carbenoxolone disodium | 7421-40-1 | 5 mg | 225元 |
| 2026/09/15 | HY-B1367 | 甘珀酸钠 Carbenoxolone disodium | 7421-40-1 | 10mM * 1mLin DMSO | 304元 |
| 2026/09/15 | HY-B1367 | 甘珀酸钠 Carbenoxolone disodium | 7421-40-1 | 10 mg | 360元 |
常见问题列表
IC50: human 11β-HSD; bacterial 3α, 20β-HSD; gap junction; Vaccinia virus
Carbenoxolone disodium (6-150 μM; pre-treatment 1 hour) inhibits Vaccinia virus (VACV) replication in a gap junction-independent in HaCaT cells, and it has toxicity effects on VACV-A5L-EGFP infected cells at 48 h.Carbenoxolone (30 μM; pre-treatment 1 hour) does not upregulate PP2A expression, but induces the late protein A27 expression in hacat cells.
Cell Viability Assay
| Cell Line: | HaCaT cells |
| Concentration: | 6 μM, 12 μM, 30 μM, 60 μM, 150 μM |
| Incubation Time: | Pre-treatment 1 hour |
| Result: | Had no toxicity until 48 hours at high dose in virus-infected cells. |
Western Blot Analysis
| Cell Line: | HaCaT cells |
| Concentration: | 30 μM |
| Incubation Time: | Pre-treatment 1 hour |
| Result: | Presented an obvious upregulation of A27. |
Carbenoxolone (intraperitoneal injection; 100, 200 and 300 mg/kg; 30, 60 and 60 min before Diazepam) does not induce a muscle relaxant activity and shows muscle relaxant activity compared to normal saline, and this effect was more than diazepam in the traction test.Carbenoxolone (intraperitoneal injection; 100, 200 and 300 mg/kg; 30, 60 and 60 min before Pentylenetetrazole) significantly increases sleeping time and decreases latency in mice as a dose-dependent manner in Pentylenetetrazole (PTZ) Seizure model. The ED 50 value is 83.3 mg/kg (%95 CL:556.29).
| Animal Model: | Male BALB/c mice |
| Dosage: | 100, 200 and 300 mg/kg |
| Administration: | Intraperitoneal injection; 30, 60 and 60 min before Pentylenetetrazole |
| Result: | Significantly increased the sleeping time in mice. |
